post image

Immuno-Oncology Drugs Global Market 2022 Opportunities And Strategies To 2031 By Type: (Immune Checkpoint Inhibitors; Immune System Modulators; Other Monoclonal Antibodies; Cancer Vaccines); By Therapeutic Application; By End-Users

  • Report ID: 43246
  • Date: Sep, 2022
  • Pages: 304
  • Category: Healthcare & Pharmaceuticals

 

Immuno-Oncology Drugs Global Market Opportunities And Strategies To 2031 from Altus Market Research provides the strategists; marketers and senior management with the critical information they need to assess the global immuno-oncology drugs market as it emerges from the COVID 19 shut down.

The global immuno-oncology drugs market reached a value of nearly $67,882.2 million in 2021, having increased at a compound annual growth rate (CAGR) of 19.5% since 2016. The market is expected to grow from $67,882.2 million in 2021 to $116,237.0 million in 2026 at a rate of 11.4%. The market is then expected to grow at a CAGR of 10.0% from 2026 and reach $186,918.8 million in 2031.

Growth in the historic period in the immuno-oncology drugs market resulted from the rise in the number of cancer cases, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure. The market was restrained by high cost of immuno-oncology therapies, low healthcare access, pricing pressures from regulators, high R&D costs, and patent expiration of drugs.

Going forward, increasing investment in immuno-oncology, rising focus on immunotherapy drugs for cancer treatment, product innovations through strategic collaborations and increasing geriatric population are expected to drive the market. Factors that could hinder the growth of the market in the future include side effects associated with immunotherapies and rising popularity of alternative therapies and natural remedies.

The immuno-oncology drugs market is segmented by type into Immune checkpoint inhibitors, immune system modulators, other monoclonal antibodies, cancer vaccines, and others. The other monoclonal antibodies segment was the largest segment of the immuno-oncology drugs market segmented by type, accounting for 40.3% of the total in 2021. Going forward, the others segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by type, at a CAGR of 26.8% during 2021-2026.

The immuno-oncology drugs market is also segmented by therapeutic application into melanoma, lung cancer, blood cancer, renal cell carcinoma, bladder cancer and other therapeutic application. The other therapeutic application was the largest segment of the immuno-oncology drugs market segmented by therapeutic application, accounting for 37.9% of the total in 2021. Going forward, the bladder cancer segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by therapeutic application, at a CAGR of 20.7% during 2021-2026.

The immuno-oncology drugs market is also segmented by end-users into hospitals, clinics, ambulatory surgical centers and others end user. The hospitals segment was the largest segment of the immuno-oncology drugs market segmented by end-users, accounting for 45.7% of the total in 2021. Going forward, hospitals segment is expected to be the fastest growing segment in the immuno-oncology drugs market segmented by end-users, at a CAGR of 11.8% during 2021-2026.

North America was the largest region in the immuno-oncology drugs market, accounting for 48.3% of the total in 2021. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the immuno-oncology drugs market will be Middle East and South America where growth will be at CAGRs of 14.0% and 12.8% respectively during 2021-2026. These will be followed by Africa and Eastern Europe, where the markets are expected to register CAGRs of 12.5% and 12.2% respectively during 2021-2026.

The global immuno-oncology drugs market is highly consolidated with a small number of large players dominating the market. The top ten competitors in the market made up to 96.84% of the total market in 2020. Major players in the market include F. Hoffmann-La Roche, Merck & Co, Bristol-Myers Squibb, Amgen Inc, and Johnson & Johnson.

The top opportunities in the immuno-oncology drugs market segmented by type will arise in other monoclonal antibodies segment, which will gain $17,982.0 of global annual sales by 2026. The top opportunities in the immuno-oncology drugs market segmented by therapeutic application will arise in other therapeutic application segment, which will gain $15,867.8 million of global annual sales by 2026. The top opportunities in the immuno-oncology drugs market segmented by end-users will arise in hospitals segment, which will gain $23,174.2 million of global annual sales by 2026. The immuno-oncology drugs market size will gain the most in the USA at $22,184.1 million.

Market-trend-based strategies for the immuno-oncology drugs include companies should develop microneedle injector-based drugs to increase the bioavailability and eliminate side effects of the subcutaneous route, consider investing in developing personalized oncology drugs to treat specific patients, consider investing in acquisitions to increase market shares and expand their product portfolio offerings, focus efforts on the development of next-generation biologics to increase revenue and market share, focus on the development of antibody-drug conjugates to manufacture medicines for cancer treatment, invest in AI solutions, reduce R&D costs and save development time, invest in 3D printing devices to test new oncology drugs, opt for immune-oncology combination therapies to boost innovation and establish category leadership, and implement CAR-T therapies to boost innovations and establish category leadership.

Player-adopted strategies in the immuno-oncology drugs market include focusing on developing and launching new combinational drug therapies, improving presence in the immuno-oncology market through strategic partnerships, strengthening immune-oncology business through product licensing and acquisitions, and evaluating and advancing new technologies to change the treatment models and offer efficacious therapies in the field of immuno-oncology by creating strategic alliances.

To take advantage of the opportunities, Altus Market Research recommends the immuno-oncology drugs companies to focus on new product launches, focus on immuno-oncology combination therapies, expand in emerging markets, increase merger and acquisition activity, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, offer value-based pricing, focus on educating consumers about immuno-oncology drugs and focus on the elderly population.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Description:

Where is the largest and fastest growing market for immuno-oncology drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The immuno-oncology drugs market global report from Altus Market Research answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider immuno-oncology drugs market; and compares it with other markets.

The report covers the following chapters

Executive Summary – The executive summary section of the report gives a brief overview and summary of the report

Report Structure – This section gives the structure of the report and the information covered in the various sections.

Introduction – The introduction section of the report gives brief introduction about segmentation by geography, segmentation by type, segmentation by therapeutic application, and segmentation by end users.

Market Characteristics – The market characteristics section of the report defines and explains the immuno-oncology drugs market. This chapter also defines and describes goods and related services covered in the report.

Trends And Strategies – This chapter describes the major trends shaping the global immuno-oncology drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.

Impact of COVID-19 – This section describes the impact of COVID-19 on the immuno-oncology drugs market.

Global Market Size And Growth – This section contains the global historic (2016-2021) and forecast (2021-2026), and (2026-2031) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.

Regional Analysis – This section contains the historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values and growth and market share comparison by region.

Segmentation – This section contains the market values (2016-2031) and analysis for different segments.

Regional Market Size and Growth – This section contains the region’s market size (2021), historic (2016-2021) and forecast (2021-2026, and 2026-2031) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.

Competitive Landscape – This section covers details on the competitive landscape of the global immuno-oncology drugs market, estimated market shares and company profiles for the leading players.

AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center (Moscow), Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar , NewBridge Pharmaceuticals, Eurolab

Key Mergers And Acquisitions – This section gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.

Market Opportunities And Strategies – This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
Conclusion and Recommendations – This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for immuno-oncology drugs providers in terms of product offerings, geographic expansion, marketing strategies and target groups.

Appendix – This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:
1) By Type: Immune Checkpoint Inhibitors; Immune System Modulators; Other Monoclonal Antibodies; Cancer Vaccines; Others
2) By Therapeutic Application: Melanoma; Lung Cancer; Blood Cancer; Renal Cell Carcinoma; Bladder Cancer; Other Therapeutic Application
3) By End-Users: Hospitals; Clinics; Ambulatory Surgical Centers; Others

Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co.; Bristol-Myers Squibb Company; Amgen Inc; Johnson & Johnson

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; immuno-oncology drugs indicators comparison.

Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

1. Immuno-Oncology Drugs Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

6.1. Segmentation By Geography

6.2. Segmentation By Type

6.3. Segmentation By Therapeutic Application

6.4. Segmentation By End Users

7. Immuno-Oncology Drugs Market Characteristics

7.1. Market Definition

7.2. Market Segmentation By Type

7.2.1. Immune Checkpoint Inhibitors

7.2.2. Immune System Modulators

7.2.3. Other Monoclonal Antibodies

7.2.4. Cancer Vaccines

7.2.5. Others

7.3. Market Segmentation By Therapeutic Application

7.3.1. Melanoma

7.3.2. Lung Cancer

7.3.3. Blood Cancer

7.3.4. Renal Cell Carcinoma

7.3.5. Prostate Cancer

7.3.6. Bladder Cancer

7.3.7. Others

7.4. Market Segmentation By End User

7.4.1. Hospitals

7.4.2. Clinics

7.4.3. Ambulatory Surgical Centers

7.4.4. Cancer Research Institutes

8. Immuno-Oncology Drugs Market Trends and Strategies

8.1. Increasing Usage of Microneedle Pills

8.2. Development Of Personalized Cancer Vaccines

8.3. Increase In Acquisition Activity Among Immuno-Oncology Drug Market Players

8.4. Development And Increasing Demand For Next-Generation Biologics

8.5. Investment In Artificial Intelligence For Oncology Drugs

8.6. Use Of 3D Printing To Test New Oncology Drugs

8.7. Immuno-Oncology Combination Therapies

8.8. CAR-T Cell Therapy

9. COVID Impact On The Immuno-Oncology Drugs Market

9.1. COVID-19 Pandemic Effects On Cancer Patients and Survivors

9.2. Clinical Trial Delays

9.3. Low Usage Of Drugs

9.4. Supply Chain Issues

9.5. Future Outlook

10. Global Immuno-Oncology Drugs Market Size And Growth

10.1. Market Size

10.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

10.2.1. Drivers Of The Market 2016-2021

10.2.2. Restraints On The Market 2016 – 2021

10.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

10.3.1. Drivers Of The Market 2021 – 2026

10.3.2. Restraints On The Market 2021 – 2026

11. Global Immuno-Oncology Drugs Market Segmentation

11.1. Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.2. Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.3. Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12. Immuno-Oncology Drugs Market, Regional And Country Analysis

12.1. Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.2. Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13. Asia-Pacific Immuno-Oncology Drugs Market

13.1. Asia-Pacific Immuno-Oncology Drugs Market Overview

13.1.1. Region Information

13.1.2. Market Information

13.1.3. Background Information

13.1.4. Government Initiatives

13.1.5. Regulations

13.1.6. Regulatory Bodies

13.1.7. Major Associations

13.1.8. Taxes Levied

13.1.9. Corporate Tax Structure

13.1.10. Investments

13.1.11. Major Companies

13.2. Asia-Pacific Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.3. Asia-Pacific Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.4. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.5. Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.6. Asia-Pacific Immuno-Oncology Drugs Market: Country Analysis

13.7. China Immuno-Oncology Drugs Market

13.8. China Immuno-Oncology Drugs Market Overview

13.8.1. Region Information

13.8.2. Market Information

13.8.3. Background Information

13.8.4. Government Initiatives

13.8.5. Regulations

13.8.6. Regulatory Bodies

13.8.7. Major Associations

13.8.8. Taxes Levied

13.8.9. Corporate Tax Structure

13.8.10. Investments

13.8.11. Major Companies

13.9. China Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.10. China Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.11. China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.12. China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.13. India Immuno-Oncology Drugs Market

13.14. India Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.15. India Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.16. India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.17. India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.18. Japan Immuno-Oncology Drugs Market

13.19. Japan Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.20. Japan Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.21. Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.22. Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.23. Australia Immuno-Oncology Drugs Market

13.24. Australia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.25. Australia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.26. Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.27. Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.28. Indonesia Immuno-Oncology Drugs Market

13.29. Indonesia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.30. Indonesia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.31. Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.32. Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.33. South Korea Immuno-Oncology Drugs Market

13.34. South Korea Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.35. South Korea Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.36. South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.37. South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14. Western Europe Immuno-Oncology Drugs Market

14.1. Western Europe Immuno-Oncology Drugs Market Overview

14.1.1. Region Information

14.1.2. Market Information

14.1.3. Background Information

14.1.4. Government Initiatives

14.1.5. Regulations

14.1.6. Regulatory Bodies

14.1.7. Major Associations

14.1.8. Taxes Levied

14.1.9. Corporate Tax Structure

14.1.10. Investments

14.1.11. Major Companies

14.2. Western Europe Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.3. Western Europe Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.4. Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.5. Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.6. Western Europe Immuno-Oncology Drugs Market: Country Analysis

14.7. UK Immuno-Oncology Drugs Market

14.8. UK Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.9. UK Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.10. UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.11. UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.12. Germany Immuno-Oncology Drugs Market

14.13. Germany Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.14. Germany Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.15. Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.16. Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.17. France Immuno-Oncology Drugs Market

14.18. France Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.19. France Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.20. France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.21. France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15. Eastern Europe Immuno-Oncology Drugs Market

15.1. Eastern Europe Immuno-Oncology Drugs Market Overview

15.1.1. Region Information

15.1.2. Market Information

15.1.3. Background Information

15.1.4. Government Initiatives

15.1.5. Regulations

15.1.6. Regulatory Bodies

15.1.7. Major Associations

15.1.8. Taxes Levied

15.1.9. Corporate Tax Structure

15.1.10. Investments

15.1.11. Major Companies

15.2. Eastern Europe Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

15.3. Eastern Europe Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

15.4. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.5. Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.6. Eastern Europe Immuno-Oncology Drugs Market: Country Analysis

15.7. Russia Immuno-Oncology Drugs Market

15.8. Russia Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

15.9. Russia Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

15.10. Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.11. Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16. North America Immuno-Oncology Drugs Market

16.1. North America Immuno-Oncology Drugs Market Overview

16.1.1. Region Information

16.1.2. Market Information

16.1.3. Background Information

16.1.4. Government Initiatives

16.1.5. Regulations

16.1.6. Regulatory Bodies

16.1.7. Major Associations

16.1.8. Taxes Levied

16.1.9. Corporate Tax Structure

16.1.10. Investments

16.1.11. Major Companies

16.2. North America Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

16.3. North America Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

16.4. North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16.5. North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16.6. North America Immuno-Oncology Drugs Market: Country Analysis

16.7. USA Immuno-Oncology Drugs Market

16.8. USA Immuno-Oncology Drugs Market Overview

16.8.1. Region Information

16.8.2. Market Information

16.8.3. Background Information

16.8.4. Government Initiatives

16.8.5. Regulations

16.8.6. Regulatory Bodies

16.8.7. Major Associations

16.8.8. Taxes Levied

16.8.9. Corporate Tax Structure

16.8.10. Investments

16.8.11. Major Companies

16.9. USA Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

16.10. USA Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

16.11. USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16.12. USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17. South America Immuno-Oncology Drugs Market

17.1. South America Immuno-Oncology Drugs Market Overview

17.1.1. Region Information

17.1.2. Market Information

17.1.3. Background Information

17.1.4. Government Initiatives

17.1.5. Regulations

17.1.6. Regulatory Bodies

17.1.7. Major Associations

17.1.8. Taxes Levied

17.1.9. Corporate Tax Structure

17.1.10. Investments

17.1.11. Major Companies

17.2. South America Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

17.3. South America Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

17.4. South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17.5. South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17.6. South America Immuno-Oncology Drugs Market: Country Analysis

17.7. Brazil Immuno-Oncology Drugs Market

17.8. Brazil Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

17.9. Brazil Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

17.10. Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17.11. Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

18. Middle East Immuno-Oncology Drugs Market

18.1. Middle East Immuno-Oncology Drugs Market Overview

18.1.1. Region Information

18.1.2. Market Information

18.1.3. Background Information

18.1.4. Government Initiatives

18.1.5. Regulations

18.1.6. Regulatory Bodies

18.1.7. Major Associations

18.1.8. Taxes Levied

18.1.9. Corporate Tax Structure

18.1.10. Investments

18.1.11. Major Companies

18.2. Middle East Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

18.3. Middle East Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

18.4. Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

18.5. Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

19. Africa Immuno-Oncology Drugs Market

19.1. Africa Immuno-Oncology Drugs Market Overview

19.1.1. Region Information

19.1.2. Market Information

19.1.3. Background Information

19.1.4. Government Initiatives

19.1.5. Regulations

19.1.6. Regulatory Bodies

19.1.7. Major Associations

19.1.8. Taxes Levied

19.1.9. Corporate Tax Structure

19.1.10. Investments

19.1.11. Major Companies

19.2. Africa Immuno-Oncology Drugs Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

19.3. Africa Immuno-Oncology Drugs Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

19.4. Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

19.5. Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

20. Global Immuno-Oncology Drugs Market Competitive Landscape

20.1. Company Profiles

20.2. F. Hoffmann-La Roche Ltd. (Roche)

20.2.1. Company Overview

20.2.2. Products And Services

20.2.3. Business Strategy

20.2.4. Financial Overview

20.3. Merck & Co.

20.3.1. Company Overview

20.3.2. Products And Services

20.3.3. Business Strategy

20.3.4. Financial Overview

20.4. Bristol-Myers Squibb Company

20.4.1. Company Overview

20.4.2. Products And Services

20.4.3. Business Strategy

20.4.4. Financial Overview

20.5. Amgen Inc

20.5.1. Company Overview

20.5.2. Products And Services

20.5.3. Business Strategy

20.5.4. Financial Overview

20.6. Johnson & Johnson (J&J)

20.6.1. Company Overview

20.6.2. Products And Services

20.6.3. Business Strategy

20.6.4. Financial Overview

21. Key Mergers And Acquisitions In The Immuno-Oncology Drugs Market

21.1. Sanofi Acquired Amunix Pharmaceuticals Inc.

21.2. Takeda Yet To Acquire Adaptate Biotherapeutics

21.3. Takeda Acquired GammaDelta Therapeutics

21.4. Pfizer Acquired Trillium Therapeutics

21.5. Amgen Acquired Teneobio Inc.

21.6. True North Acquired Stake In Biocon Biologics Ltd.

21.7. PAG Acquired Stake In Hisun BioRay

21.8. Eli Lilly And Company Acquired Loxo Oncology, Inc.

21.9. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

21.10. Bristol-Myers Squibb Acquired Celgene Corporation

21.11. Kashiv Pharma, LLC Acquired Adello Biologics

21.12. Takeda Pharmaceutical Company Limited Acquired Shire Plc

21.13. GlaxoSmithKline Plc Acquired Tesaro Inc.

22. Immuno-Oncology Drugs Market Opportunities And Strategies

22.1. Global Immuno-Oncology Drugs Market In 2026 – Countries Offering Most New Opportunities

22.2. Global Immuno-Oncology Drugs Market In 2026 – Segments Offering Most New Opportunities

22.3. Global Immuno-Oncology Drugs Market In 2026 – Growth Strategies

22.3.1. Market Trend Based Strategies

22.3.2. Competitor Strategies

23. Immuno-Oncology Drugs Market, Conclusions And Recommendations

23.1. Conclusions

23.2. Recommendations

23.2.1. Product

23.2.2. Place

23.2.3. Price

23.2.4. Promotion

23.2.5. People

24. Appendix

24.1. Market Data Sources

24.2. Research Methodology

24.3. Currencies

24.4. Research Inquiries

24.5. The Business Research Company

24.6. Copyright and Disclaimer

24.7.


List of Tables

Table 1: Global Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 2: Global Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 3: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 4: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 5: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 6: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 7: Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 8: Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 9: Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
Table 10: Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 11: Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
Table 12: Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 13: Asia Pacific GDP Per Capita, 2015-2020, $
Table 14: Asia-Pacific, Population By Age Group, By Country, 2015-2025, Thousands
Table 15: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
Table 16: Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
Table 17: Asia-Pacific Healthcare Services Market Size, 2016-2026, $ Billion
Table 18: Asia Pacific Cancer Prevalence, Estimated Average Expenditure, 2019, $
Table 19: Asia-Pacific Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 20: Asia-Pacific Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 21: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 22: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 23: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 24: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 25: China GDP Per Capita, 2015-2020, $
Table 26: China, Population By Age Group, 2015-2025, Thousands
Table 27: China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
Table 28: China Healthcare Services Market Size, 2016-2026, $ Billion
Table 29: China Cancer Prevalence, Estimated Average Expenditure, 2019, $
Table 30: China Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 31: China Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 32: China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 33: China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 34: China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 35: China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 36: India Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 37: India Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 38: India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 39: India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 40: India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 41: India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 42: Japan Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 43: Japan Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 44: Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 45: Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 46: Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 47: Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 48: Australia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 49: Australia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 50: Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 51: Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 52: Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 53: Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 54: Indonesia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 55: Indonesia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 56: Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 57: Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 58: Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 59: Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 60: South Korea Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 61: South Korea Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 62: South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 63: South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 64: South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 65: South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 66: Western Europe GDP Per Capita, 2015-2020, $
Table 67: Western Europe, Population By Age Group, By Country, 2015-2025, Thousands
Table 68: Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
Table 69: Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
Table 70: Western Europe Healthcare Services Market Size, 2016-2026, $ Billion
Table 71: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
Table 72: Western Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 73: Western Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 74: Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 75: Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 76: Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 77: Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 78: UK Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 79: UK Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 80: UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 81: UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 82: UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 83: UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 84: Germany Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 85: Germany Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 86: Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 87: Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 88: Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 89: Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 90: France Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 91: France Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 92: France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 93: France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 94: France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 95: France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 96: Eastern Europe GDP Per Capita, 2015-2020, $
Table 97: Eastern Europe, Population By Age Group, By Country, 2015-2025, Thousands
Table 98: Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
Table 99: Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
Table 100: Eastern Europe Healthcare Services Market Size, 2016-2026, $ Billion
Table 101: Eastern Europe Estimated Average Expenditure, Cancer Prevalence, 2019
Table 102: Eastern Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 103: Eastern Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 104: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 105: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 106: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 107: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 108: Russia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 109: Russia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 110: Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 111: Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 112: Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 113: Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 114: North America GDP Per Capita, 2015-2020, $
Table 115: North America, Population By Age Group, By Country, 2015-2025, Thousands
Table 116: North America Public Healthcare Expenditure, 2015-2020, $ Billion
Table 117: North America Private Healthcare Expenditure, 2015-2020, $ Billion
Table 118: North America Healthcare Services Market Size, 2016-2026, $ Billion
Table 119: North America Estimated Average Expenditure, Cancer Prevalence, 2019
Table 120: North America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 121: North America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 122: North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 123: North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 124: North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 125: North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 126: USA GDP Per Capita, 2015-2020, $
Table 127: USA, Population By Age Group, 2015-2025, Thousands
Table 128: USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
Table 129: USA Healthcare Services Market Size, 2016-2026, $ Billion
Table 130: North America Estimated Average Expenditure, Cancer Prevalence, 2019
Table 131: USA Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 132: USA Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 133: USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 134: USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 135: USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 136: USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 137: South America GDP Per Capita, 2015-2020, $
Table 138: South America, Population By Age Group, By Country, 2015-2025, Thousands
Table 139: South America Public Healthcare Expenditure, 2015-2020, $ Billion
Table 140: South America Private Healthcare Expenditure, 2015-2020, $ Billion
Table 141: South America Healthcare Services Market Size, 2016-2026, $ Billion
Table 142: South America Estimated Average Expenditure, Cancer Prevalence, 2019
Table 143: South America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 144: South America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 145: South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 146: South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 147: South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 148: South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 149: Brazil Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 150: Brazil Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 151: Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 152: Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 153: Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 154: Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 155: Middle East GDP Per Capita, 2015-2020, $
Table 156: Middle East, Population By Age Group, By Country, 2015-2025, Thousands
Table 157: Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
Table 158: Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
Table 159: Middle East Healthcare Services Market Size, 2016-2026, $ Billion
Table 160: Middle East Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 161: Middle East Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 162: Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 163: Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 164: Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 165: Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 166: Africa GDP Per Capita, 2015-2020, $
Table 167: Africa, Population By Age Group, By Country, 2015-2025, Thousands
Table 168: Africa Public Healthcare Expenditure, 2015-2020, $ Billion
Table 169: Africa Private Healthcare Expenditure, 2015-2020, $ Billion
Table 170: Africa Healthcare Services Market Size, 2016-2026, $ Billion
Table 171: Africa Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million
Table 172: Africa Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million
Table 173: Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 174: Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 175: Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
Table 176: Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
Table 177: Global Immuno-Oncology Drugs Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
Table 178: F. Hoffmann-La Roche Ltd – Financial Performance, $ Billion
Table 179: Merck & Co – Financial Performance, $ Billion
Table 180: Bristol-Myers Squibb – Financial Performance, $ Billion
Table 181: Amgen – Financial Performance, $ Billion
Table 182: J&J – Financial Performance, $ Billion
Table 183: Global Immuno-Oncology Drugs Market Size Gain ($ Million), 2021 – 2026, By Country
Table 184: Global Immuno-Oncology Drugs Market Size Gain ($ Million), Segmentation By Type, 2021 – 2026
Table 185: Global Immuno-Oncology Drugs Market Size Gain ($ Million), Segmentation By Therapeutic Application, 2021 – 2026
Table 186: Global Immuno-Oncology Drugs Market Size Gain ($ Million), Segmentation By End User, 2021 – 2026
Table 187: Immuno-Oncology Drugs - Market Data Sources


List of Figures

Figure 1: Global Immuno-Oncology Drugs Market Segmentation By Type

Figure 2: Global Immuno-Oncology Drugs Market Segmentation By Therapeutic Application

Figure 3: Global Immuno-Oncology Drugs Market Segmentation By End Users

Figure 4: Global Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 5: Global Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 6: Global Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 7: Global Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 8: Global Immuno-Oncology Drugs Market, Segmentation By End User, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 9: Global Immuno-Oncology Drugs Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 10: Global Immuno-Oncology Drugs Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 11: Asia-Pacific Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 12: Asia-Pacific Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 13: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 14: Asia-Pacific Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 15: China Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 16: China Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 17: China Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 18: China Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 19: India Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 20: India Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 21: India Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 22: India Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 23: Japan Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 24: Japan Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 25: Japan Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 26: Japan Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 27: Australia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 28: Australia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 29: Australia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 30: Australia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 31: Indonesia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 32: Indonesia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 33: Indonesia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 34: Indonesia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 35: South Korea Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 36: South Korea Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 37: South Korea Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 38: South Korea Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 39: Western Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 40: Western Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 41: Western Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 42: Western Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 43: UK Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 44: UK Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 45: UK Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 46: UK Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 47: Germany Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 48: Germany Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 49: Germany Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 50: Germany Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 51: France Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 52: France Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 53: France Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 54: France Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 55: Eastern Europe Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 56: Eastern Europe Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 57: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 58: Eastern Europe Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 59: Russia Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 60: Russia Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 61: Russia Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 62: Russia Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 63: North America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 64: North America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 65: North America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 66: North America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 67: USA Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 68: USA Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 69: USA Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 70: USA Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 71: South America Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 72: South America Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 73: South America Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 74: South America Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 75: Brazil Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 76: Brazil Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 77: Brazil Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 78: Brazil Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 79: Middle East Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 80: Middle East Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 81: Middle East Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 82: Middle East Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 83: Africa Immuno-Oncology Drugs Market, Historic, 2016 – 2021, $ Million

Figure 84: Africa Immuno-Oncology Drugs Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 85: Africa Immuno-Oncology Drugs Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 86: Africa Immuno-Oncology Drugs Market, Segmentation By Therapeutic Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 87: Global Immuno-Oncology Drugs Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)

Figure 88: F. Hoffmann-La Roche Ltd.– Financial Performance, $ Billion

Figure 89: Merck & Co – Financial Performance, $ Billion

Figure 90: Bristol-Myers Squibb – Financial Performance, $ Billion

Figure 91: Amgen – Financial Performance, $ Billion

Figure 92: J&J – Financial Performance, $ Billion

Research methodology is mainly referring to the practical how of any offered piece of research. More specifically, it’s all about how a researcher systematically designs a study in order to assure extremely valid as well as reliable results that ultimately address the targets and objectives of the research.

In any formal research including academic journal, article, dissertation and so on, there will be a special section on a research methodology that mainly describes what, by whom, how to gather as well as how to evaluate the data are provided.

This research methodology has been segmented into following types:

Primary Research:

It is said to be original information that the researchers collect for the crucial purposes of answering the research questions of readers with the help of surveys, observations and experiments.

Secondary Research:

The secondary research is the data that has already been collected by various other researchers in the form of government analysis or scientific studies.

Qualitative Research:

It is descriptive and subjective method irrespective of facts. Both observation and description are essential in this type of research methodology. Its main vision is to analyze knowledge, attitudes, behaviours as well as opinions of people related to the topic of any research. This method has been operated through grounded research, case study and actionable research.

Quantitative Research:

It contains several laboratory experiments, basic surveys, mathematical calculations, simulations and so on. The possible measurement, quantity or amount is considered to be a major factor in the quantitative research methodology.

Tab Four
Our Happy

Clients